Future Perspectives for the Treatment of Pulmonary Arterial Hypertension

被引：62

作者：

Ghofrani, Hossein A. ^{[1
,2
,7
]}

Barst, Robyn J. ^{[3
]}

Benza, Raymond L. ^{[4
]}

Champion, Hunter C. ^{[5
]}

Fagan, Karen A. ^{[6
]}

Grimminger, Friedrich ^{[2
,7
]}

Humbert, Marc ^{[8
]}

Simonneau, Gerald ^{[8
]}

Stewart, Duncan J. ^{[9
]}

Ventura, Carlo ^{[10
]}

Rubin, Lewis J. ^{[11
]}

机构：

[1] Univ Giessen, Lung Ctr, Pulm Hypertens Div, Univ Hosp Giessen,Med Clin 2 5, D-35392 Giessen, Germany

[2] Marburg GmbH, Giessen, Germany

[3] Columbia Univ, New York, NY USA

[4] Drexel Univ, Coll Med, Sect Heart Failure Transplantat & Pulm, Hypertens Program,Allegheny Gen Hosp, Pittsburgh, PA USA

[5] Johns Hopkins Univ, Div Cardiol, Baltimore, MD USA

[6] Univ S Alabama, Div Pulm & Crit Care Med, Mobile, AL 36688 USA

[7] Univ Hosp Giessen, Med Clin 4 & 5, D-35392 Giessen, Germany

[8] Univ Paris Sud, Hop Antoine Beclere, Serv Pneumol, Clamart, France

[9] Ottawa Hlth Res Inst, Ottawa, ON, Canada

[10] Univ Bologna, Lab Mol Biol & Stem Cell Engn, Natl Inst Biostruct & Biosyst, Inst Cardiol,S Orsola Malpighi Hosp, Bologna, Italy

[11] Univ Calif San Diego, Med Ctr, La Jolla, CA 92093 USA

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2009年 / 54卷 / 01期

关键词：

treatment; pulmonary arterial hypertension; PAH; NITRIC-OXIDE SYNTHASE; ENDOTHELIAL GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; ATRIAL-NATRIURETIC-PEPTIDE; PROTEIN-COUPLED RECEPTORS; GATED K+ CHANNELS; TGF-BETA FAMILY; NADPH OXIDASE; MYOCARDIAL-INFARCTION; CHRONIC HYPOXIA;

D O I：

10.1016/j.jacc.2009.04.014

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Over the past 2 decades, pulmonary arterial hypertension has evolved from a uniformly fatal condition to a chronic, manageable disease in many cases, the result of unparalleled development of new therapies and advances in early diagnosis. However, none of the currently available therapies is curative, so the search for new treatment strategies continues. With a deeper understanding of the genetics and the molecular mechanisms of pulmonary vascular disorders, we are now at the threshold of entering a new therapeutic era. Our working group addressed what can be expected in the near future. The topics span the understanding of genetic variations, novel antiproliferative treatments, the role of stem cells, the right ventricle as a therapeutic target, and strategies and challenges for the translation of novel experimental findings into clinical practice. (J Am Coll Cardiol 2009;54:S108-17) (C) 2009 by the American College of Cardiology Foundation

引用

页码：S108 / S117

页数：10

共 135 条

[71] Functional consequences of tumorigenic missense mutations in the amino-terminal domain of Smad4 [J].

Morén, A ;

Itoh, S ;

Moustakas, A ;

ten Dijke, P ;

Heldin, CH .

ONCOGENE, 2000, 19 (38) :4396-4404

[72] Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension [J].

Moreno-Vinasco, Liliana ;

Gomberg-Maitland, Mardi ;

Maitland, Michael L. ;

Desai, Ankit A. ;

Singleton, Patrick A. ;

Sammani, Saad ;

Sam, Lee ;

Liu, Yang ;

Husain, Aliya N. ;

Lang, Roberto M. ;

Ratain, Mark J. ;

Lussier, Yves A. ;

Garcia, Joe G. N. .

PHYSIOLOGICAL GENOMICS, 2008, 33 (02) :278-291

[73] Altered growth responses of muscle cells from patients pulmonary artery smooth with primary pulmonary hypertension to transforming growth factor-β1 and bone morphogenetic proteins [J].

Morrell, NW ;

Yang, XD ;

Upton, PD ;

Jourdan, KB ;

Morgan, N ;

Sheares, KK ;

Trembath, RC .

CIRCULATION, 2001, 104 (07) :790-795

[74] Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by bone morphogenetic protein-2 [J].

Nakaoka, T ;

Gonda, K ;

Ogita, T ;

Otawara-Hamamoto, Y ;

Okabe, F ;

Kira, Y ;

Harii, K ;

Miyazono, K ;

Takuwa, Y ;

Fujita, T .

JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (11) :2824-2832

[75] Never polymorphic CA/TG repeat identified in the human prostacyclin synthase gene [J].

Nakayama, T ;

Soma, M ;

Takahashi, Y ;

Uwabo, J ;

Izumi, Y ;

Kanmatsuse, K .

HUMAN HEREDITY, 1997, 47 (03) :176-177

[76] Polymorphisms of the endothelin-A and -B receptor genes in relation to blood pressure and myocardial infarction - The Etude Cas-Temoins sur l'Infarctus du Myocarde (ECTIM) Study [J].

Nicaud, V ;

Poirier, O ;

Behague, I ;

Herrmann, SM ;

Mallet, C ;

Troesch, A ;

Bouyer, J ;

Evans, A ;

Luc, G ;

Ruidavets, JB ;

Arveiler, D ;

Bingham, A ;

Tiret, L ;

Cambien, F .

AMERICAN JOURNAL OF HYPERTENSION, 1999, 12 (03) :304-310

[77] 40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats [J].

Nishimura, T ;

Faul, JL ;

Berry, GI ;

Veve, I ;

Pearl, RG ;

Kao, PN .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 163 (02) :498-502

[78] Rapamycin attenuates hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy in mice [J].

Paddenberg, Renate ;

Stieger, Philipp ;

von Lilien, Anna-Laura ;

Faulhammer, Petra ;

Goldenberg, Anna ;

Tillmanns, Harald H. ;

Kummer, Wolfgang ;

Braun-Dullaeus, Ruediger C. .

RESPIRATORY RESEARCH, 2007, 8 (1)

[79] Clinical implications for Vascular Endothelial Growth Factor in the lung: friend or foe? [J].

Papaioannou, Andriana I. ;

Kostikas, Konstantinos ;

Kollia, Panagoula ;

Gourgoulianis, Konstantinos I. .

RESPIRATORY RESEARCH, 2006, 7 (1)

[80] CARDIAC DYNAMICS [J].

PARMLEY, WW ;

TYBERG, JV ;

GLANTZ, SA .

ANNUAL REVIEW OF PHYSIOLOGY, 1977, 39 :277-299

← 3 4 5 6 7 8 9 10 11 12 →